JP7725370B2 - Ａｎｇｐｔｌ２アンチセンスオリゴヌクレオチドおよびその使用 - Google Patents

Ａｎｇｐｔｌ２アンチセンスオリゴヌクレオチドおよびその使用

Info

Publication number
JP7725370B2
JP7725370B2 JP2021559064A JP2021559064A JP7725370B2 JP 7725370 B2 JP7725370 B2 JP 7725370B2 JP 2021559064 A JP2021559064 A JP 2021559064A JP 2021559064 A JP2021559064 A JP 2021559064A JP 7725370 B2 JP7725370 B2 JP 7725370B2
Authority
JP
Japan
Prior art keywords
aso
seq
angptl2
nucleotides
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021559064A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022524218A5 (https=
JP2022524218A (ja
JPWO2020206115A5 (https=
Inventor
アール アンダーソン，ブライアン
イー オルソン，リチャード
エム マクドナルド，アイバー
イー マーサー，スティーブン
ヘーイドーン，ピーター
レアベック イェンセン，マリアンネ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Innovation Center Copenhagen AS
Bristol Myers Squibb Co
Original Assignee
Roche Innovation Center Copenhagen AS
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Innovation Center Copenhagen AS, Bristol Myers Squibb Co filed Critical Roche Innovation Center Copenhagen AS
Publication of JP2022524218A publication Critical patent/JP2022524218A/ja
Publication of JP2022524218A5 publication Critical patent/JP2022524218A5/ja
Publication of JPWO2020206115A5 publication Critical patent/JPWO2020206115A5/ja
Priority to JP2025131153A priority Critical patent/JP2026002846A/ja
Application granted granted Critical
Publication of JP7725370B2 publication Critical patent/JP7725370B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021559064A 2019-04-03 2020-04-02 Ａｎｇｐｔｌ２アンチセンスオリゴヌクレオチドおよびその使用 Active JP7725370B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025131153A JP2026002846A (ja) 2019-04-03 2025-08-06 Ａｎｇｐｔｌ２アンチセンスオリゴヌクレオチドおよびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962828864P 2019-04-03 2019-04-03
US62/828,864 2019-04-03
PCT/US2020/026379 WO2020206115A2 (en) 2019-04-03 2020-04-02 Angptl2 antisense oligonucleotides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025131153A Division JP2026002846A (ja) 2019-04-03 2025-08-06 Ａｎｇｐｔｌ２アンチセンスオリゴヌクレオチドおよびその使用

Publications (4)

Publication Number Publication Date
JP2022524218A JP2022524218A (ja) 2022-04-28
JP2022524218A5 JP2022524218A5 (https=) 2023-04-10
JPWO2020206115A5 JPWO2020206115A5 (https=) 2023-04-10
JP7725370B2 true JP7725370B2 (ja) 2025-08-19

Family

ID=70465458

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021559064A Active JP7725370B2 (ja) 2019-04-03 2020-04-02 Ａｎｇｐｔｌ２アンチセンスオリゴヌクレオチドおよびその使用
JP2025131153A Pending JP2026002846A (ja) 2019-04-03 2025-08-06 Ａｎｇｐｔｌ２アンチセンスオリゴヌクレオチドおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025131153A Pending JP2026002846A (ja) 2019-04-03 2025-08-06 Ａｎｇｐｔｌ２アンチセンスオリゴヌクレオチドおよびその使用

Country Status (13)

Country Link
US (1) US20220213484A1 (https=)
EP (1) EP3947680A2 (https=)
JP (2) JP7725370B2 (https=)
KR (1) KR20210149107A (https=)
CN (1) CN113906139A (https=)
AU (1) AU2020252374A1 (https=)
BR (1) BR112021019182A2 (https=)
CA (1) CA3135794A1 (https=)
EA (1) EA202192733A1 (https=)
IL (1) IL286826A (https=)
MX (1) MX2021012098A (https=)
SG (1) SG11202110745VA (https=)
WO (1) WO2020206115A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3131970B1 (fr) 2022-01-14 2024-02-23 Univ D’Aix Marseille Amu Dispositif pour la simulation en chirurgie abdominale

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059938A1 (en) 1999-04-01 2000-10-12 Genetics Institute, Inc. Angiopoietin-like proteins, crisp proteins and polynucleotides encoding same
JP2011093896A (ja) 2009-09-30 2011-05-12 Kumamoto Univ 癌治療剤
WO2014167529A1 (en) 2013-04-10 2014-10-16 Institut De Cardiologie De Montreal Methods and compositions for preventing and treating atherosclerosis
JP2015502365A (ja) 2011-12-12 2015-01-22 オンコイミューニン，インコーポレイティド オリゴヌクレオチドのイン−ビボ送達
JP2016521753A (ja) 2013-06-12 2016-07-25 オンコイミューニン，インコーポレイティド オリゴヌクレオチドの全身性イン−ビボ送達
WO2017078100A1 (ja) 2015-11-06 2017-05-11 国立大学法人熊本大学 心不全の予防又は治療のための医薬組成物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO1993007883A1 (en) 1991-10-24 1993-04-29 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
AU9063398A (en) 1997-09-12 1999-04-05 Exiqon A/S Oligonucleotide analogues
JPH11341989A (ja) * 1998-03-31 1999-12-14 Sanyo Electric Co Ltd Ｄｎａ断片増幅方法、ｄｎａ断片増幅装置、微生物群測定方法、微生物群分析方法および汚染物質測定方法
CZ296576B6 (cs) 1999-02-12 2006-04-12 Sankyo Company Limited Nukleosidový analog a oligonukleotidový analog a farmaceutický prostredek, sonda a primer s jeho obsahem
EP1178999B1 (en) 1999-05-04 2007-03-14 Santaris Pharma A/S L-ribo-lna analogues
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
US9045518B2 (en) 2002-11-18 2015-06-02 Santaris Pharma A/S Amino-LNA, thio-LNA and alpha-L-oxy-LN
CA2519860C (en) 2003-03-21 2018-01-16 Santaris Pharma A/S Short interfering rna (sirna) analogues
US20070072209A1 (en) * 2005-07-07 2007-03-29 Ashlee Moses Methods of treatment and diagnosis of Kaposi's sarcoma (KS) and KS related diseases
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
JP5342881B2 (ja) 2006-01-27 2013-11-13 アイシス ファーマシューティカルズ， インコーポレーテッド ６−修飾された二環式核酸類似体
DK1984382T3 (da) 2006-01-27 2012-09-03 Santaris Pharma As LNA modificerede fosforthiolerede oligonukleotider
WO2007107162A2 (en) 2006-03-23 2007-09-27 Santaris Pharma A/S Small internally segmented interfering rna
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
AU2007249349B2 (en) 2006-05-11 2012-03-08 Isis Pharmaceuticals, Inc. 5'-Modified bicyclic nucleic acid analogs
EP2170917B1 (en) 2007-05-30 2012-06-27 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (en) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
CA2692579C (en) 2007-07-05 2016-05-03 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
US8546556B2 (en) 2007-11-21 2013-10-01 Isis Pharmaceuticals, Inc Carbocyclic alpha-L-bicyclic nucleic acid analogs
WO2010036698A1 (en) 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
EP2403946A4 (en) * 2009-03-04 2012-11-14 TREATMENT OF SIRTUIN 1 (SIRT1) -HANDLED ILLNESSES BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPT AGAINST SIRT 1
EP2462153B1 (en) 2009-08-06 2015-07-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
EP2490699A1 (en) 2009-10-20 2012-08-29 Santaris Pharma A/S Oral delivery of therapeutically effective lna oligonucleotides
EP2580228B1 (en) 2010-06-08 2016-03-23 Ionis Pharmaceuticals, Inc. Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
PH12019502377A1 (en) * 2011-04-21 2022-11-14 Isis Pharmaceuticals Inc Modulation of hepatitis b virus (hbv) expression
EP3453761A1 (en) 2011-08-29 2019-03-13 Ionis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
EP2850092B1 (en) 2012-04-09 2017-03-01 Ionis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
US10077443B2 (en) 2012-11-15 2018-09-18 Roche Innovation Center Copenhagen A/S Oligonucleotide conjugates
DK2991656T3 (da) 2013-05-01 2020-03-23 Ionis Pharmaceuticals Inc Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression
ES2770667T3 (es) 2013-06-27 2020-07-02 Roche Innovation Ct Copenhagen As Oligómeros antisentido y conjugados que se dirigen a PCSK9
HK1244843A1 (zh) * 2014-11-17 2018-08-17 Alnylam Pharmaceuticals, Inc. 载脂蛋白c3(apoc3)irna组合物及其使用方法
AU2016215155A1 (en) * 2015-02-04 2017-08-17 F. Hoffmann-La Roche Ag Tau antisense oligomers and uses thereof
KR102645243B1 (ko) 2016-11-23 2024-03-11 알닐람 파마슈티칼스 인코포레이티드 표적외 효과가 감소된 변형 rna 작용제
UY38562A (es) * 2019-01-29 2020-08-31 Ionis Pharmaceuticals Inc Compuestos y métodos para reducir la expresión de app

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059938A1 (en) 1999-04-01 2000-10-12 Genetics Institute, Inc. Angiopoietin-like proteins, crisp proteins and polynucleotides encoding same
JP2011093896A (ja) 2009-09-30 2011-05-12 Kumamoto Univ 癌治療剤
JP2015502365A (ja) 2011-12-12 2015-01-22 オンコイミューニン，インコーポレイティド オリゴヌクレオチドのイン−ビボ送達
WO2014167529A1 (en) 2013-04-10 2014-10-16 Institut De Cardiologie De Montreal Methods and compositions for preventing and treating atherosclerosis
JP2016521753A (ja) 2013-06-12 2016-07-25 オンコイミューニン，インコーポレイティド オリゴヌクレオチドの全身性イン−ビボ送達
WO2017078100A1 (ja) 2015-11-06 2017-05-11 国立大学法人熊本大学 心不全の予防又は治療のための医薬組成物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Drug Delivary System，2019年03月25日，Vol.34-2，pp.86-98
Metabolism，2017年，Vol.69，pp.157-170
Oncology Reports，2015年，Vol.33，pp.58-66
Pharmaceutical and Medical Device Regulatory Science，2015年，Vol.46, No.10，pp.681-686

Also Published As

Publication number Publication date
AU2020252374A1 (en) 2021-11-11
IL286826A (en) 2021-10-31
JP2026002846A (ja) 2026-01-08
MX2021012098A (es) 2021-11-03
CN113906139A (zh) 2022-01-07
KR20210149107A (ko) 2021-12-08
JP2022524218A (ja) 2022-04-28
EP3947680A2 (en) 2022-02-09
SG11202110745VA (en) 2021-10-28
WO2020206115A3 (en) 2020-11-12
CA3135794A1 (en) 2020-10-08
BR112021019182A2 (pt) 2022-05-31
WO2020206115A2 (en) 2020-10-08
EA202192733A1 (ru) 2022-03-14
US20220213484A1 (en) 2022-07-07

Similar Documents

Publication Publication Date Title
JP7500426B2 (ja) Ｃａｍｋ２ｄアンチセンスオリゴヌクレオチドおよびその使用
JP2024056820A (ja) Ｓｃｎ９ａ発現を調節するためのオリゴヌクレオチド
CN112912500A (zh) 用于调节atxn2表达的寡核苷酸
CN114901821A (zh) Sept9抑制剂用于治疗乙型肝炎病毒感染的用途
JP2026002846A (ja) Ａｎｇｐｔｌ２アンチセンスオリゴヌクレオチドおよびその使用
TWI791868B (zh) 調節rtel1表現之寡核苷酸
CN114829599A (zh) Scamp3抑制剂用于治疗乙型肝炎病毒感染的用途
CN114867856A (zh) Saraf抑制剂用于治疗乙型肝炎病毒感染的用途
EA050113B1 (ru) Антисмысловые олигонуклеотиды angptl2 и их применения
CN114829601A (zh) Sbds抑制剂用于治疗乙型肝炎病毒感染的用途
JP2023506547A (ja) Ｂ型肝炎ウイルス感染を処置するためのｃｏｐｓ３阻害剤の使用
JP2023527684A (ja) 神経疾患を治療するための補体成分ｃ１ｓ阻害剤、並びにそれを使用する関連組成物、システム及び方法
EP4150084A1 (en) Complement component 4 inhibitors for treating neurological diseases, and related compositons, systems and methods of using same
US20210378652A1 (en) Camk2d antisense oligonucleotides and uses thereof
JP2024524874A (ja) オリゴヌクレオチドプログラニュリンアゴニスト
EA046329B1 (ru) Антисмысловые олигонуклеотиды camk2d и их применение
HK40084486A (en) Complement component c1s inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
JP2026074094A (ja) Ｆｕｂｐ１発現を調節するための増強されたオリゴヌクレオチド
JP2025516554A (ja) Ｃｆｐ－ｅｌｋ１遺伝子間領域を標的とするアンチセンスオリゴヌクレオチド
HK40077333A (en) Use of saraf inhibitors for treating hepatitis b virus infection
WO2021158810A1 (en) Oligonucleotides for splice modulation of camk2d
JP2023527693A (ja) 神経疾患を治療するための補体成分ｃ１ｒ阻害剤、並びに関連する組成物、システム、及びそれを使用する方法
HK40078456A (en) Use of sbds inhibitors for treating hepatitis b virus infection
JP2024546887A (ja) オリゴヌクレオチドｇｂａアゴニスト
HK40085370A (en) Complement component 4 inhibitors for treating neurological diseases, and related compositons, systems and methods of using same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230331

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240227

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240523

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241126

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250409

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250708

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250806

R150 Certificate of patent or registration of utility model

Ref document number: 7725370

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150